Marcio Covas Moschovas: S-RARP is a safe and feasible treatment option for patients with recurrent prostate cancer
Marcio Covas Moschovas, Urologist at AdventHealth Global Robotics Institute, shared on LinkedIn:
“Salvage Robotic Prostatectomy: Expertise Matters
Our latest multicenter study with the EAU Robotic Urology Section published at European Urology shows that salvage robotic-assisted radical prostatectomy (S-RARP) is a safe and feasible treatment option for patients with recurrent prostate cancer – even after complex primary therapies like radiation or ablation.
However, this procedure is not for the faint-hearted. S-RARP presents unique anatomical challenges, demands refined surgical skills, and should be performed only by highly experienced surgeons at high-volume centers.
The EAU selection criteria provide a helpful framework for identifying ideal candidates, focusing on factors such as PSA <10 ng/ml, low comorbidity burden, and localized disease. Yet, our real-world data reveal a crucial insight: many patients do not meet these ideal criteria, but still undergo S-RARP – often with acceptable outcomes.
Take-home message: Strict selection helps optimize outcomes, but expert judgment is irreplaceable. In practice, patient decisions, previous treatment frustrations, and lack of alternatives often shape who gets surgery.
Is S-RARP part of your routine?”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023